Dose optimisation in axSpA: looking to the future

Dose optimisation in axSpA

A series of modules of a panel discussion on the benefits of dose optimisation in axial spondyloarthritis (axSpA) patients.

Please login or register to access this content.

Off
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: July 2021
IE-P-CZ-AS-2100073